Search results for "TNF"

showing 10 items of 161 documents

Genetic risk profiles for Alzheimer's disease: Integration of APOE genotype and variants that up-regulate inflammation

2007

BACKGROUND: A number of studies associate Alzheimer's disease with APOE polymorphism and alleles which favor the increased expression of immunological mediators such as cytokines or acute phase proteins. We integrated this information to better define risk and determine the relative importance of APOE and immunological mediators. METHODS: We investigated functional gene variants for APOE, IL-10 (3 loci), ACT (2 loci), HMGCR, IL-1alpha, IL-1beta, TNF-alpha, IFN-gamma, and IL-6 found for 260 AD patients and 190 controls enrolled in Northern Italy. A fuzzy latent classification approach, namely grade-of-membership analysis (GoM), was taken to identify extreme pure type risk sets, or profiles. …

MaleApolipoprotein EAgingGenotypeDiseaseBiologyApolipoproteins EAlzheimer DiseaseRisk FactorsGenotypeHumansGenetic Predisposition to DiseaseCognitive declineAlleleGeneAgedAged 80 and overGeneticsPolymorphism GeneticGeneral NeuroscienceAge FactorsAcute-phase proteinGenetic VariationAPOE IL-10 ACT HMGCR IL-1alpha IL-1beta TNF-alpha IFN-gamma IL-6 SNPs Grade of memebership Genetic risk profile Alzheimer's diseaseMiddle AgedUp-RegulationFemaleNeurology (clinical)Gene polymorphismInflammation MediatorsGeriatrics and GerontologyDevelopmental Biology
researchProduct

Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

2020

Abstract Background Few data exist regarding the long‐term effectiveness of golimumab in ulcerative colitis. No data have been reported on real‐world continuous clinical response. Objective This study aimed to describe the long‐term outcomes in a large cohort of patients on golimumab who had ulcerative colitis. Methods Consecutive patients with active ulcerative colitis, started on golimumab, were enrolled and prospectively followed up. The primary end point was to evaluate the long‐term persistence on golimumab therapy. Results A total of 173 patients with ulcerative colitis were studied. Of these, 79.2% were steroid dependent, and 46.3% were naïve to anti‐tumour necrosis factor alpha agen…

AdultMalemedicine.medical_specialtyAdolescentnaïveGolimumabPersistence (computer science)03 medical and health sciencesYoung Adult0302 clinical medicineremissionGastrointestinal AgentsInternal medicinemedicineHumansProspective StudiesAgedRetrospective Studiesulcerative colitisbusiness.industryTumor Necrosis Factor-alphaInflammatory Bowel DiseaseGastroenterologyAntibodies MonoclonalpersistenceMiddle Agedmedicine.diseaseUlcerative colitisGolimumabGolimumab; naïve; persistence; remission; ulcerative colitisOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyColitis UlcerativeFemaleOriginal Articlebusinessmedicine.drugFollow-Up StudiesIBD Ulcerative colitis Golimumab TNF-inhibitors
researchProduct

The Role of Osteoprotegerin and Its Ligands in Vascular Function

2019

International audience; The superfamily of tumor necrosis factor (TNF) receptors includes osteoprotegerin (OPG) and its ligands, which are receptor activators of nuclear factor kappa-B ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). The OPG/RANKL/RANK system plays an active role in pathological angiogenesis and inflammation as well as cell survival. It has been demonstrated that there is crosstalk between endothelial cells and osteoblasts during osteogenesis, thus establishing a connection between angiogenesis and osteogenesis. This OPG/RANKL/RANK/TRAIL system acts on specific cell surface receptors, which are then able to transmit their signals to other intracellular comp…

0301 basic medicineAngiogenesismedicine.medical_treatmentReview030204 cardiovascular system & hematologyLigandslcsh:ChemistryTNF-Related Apoptosis-Inducing Ligand0302 clinical medicineReceptorlcsh:QH301-705.5Cellular SenescenceSpectroscopyReceptor Activator of Nuclear Factor-kappa BbiologyChemistryvascular diseaseGeneral MedicineComputer Science ApplicationsProtein Transportmedicine.anatomical_structureCytokineRANKLTumor necrosis factor alphaDisease Susceptibilitymedicine.symptomProtein BindingSignal Transductionmusculoskeletal diseasesProteasome Endopeptidase ComplexEndotheliumendotheliumNeovascularization PhysiologicInflammationCatalysisInorganic ChemistryStructure-Activity Relationship03 medical and health sciencesOsteoprotegerin[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyMyocardiumRANK LigandOrganic ChemistryEndothelial Cells030104 developmental biologylcsh:Biology (General)lcsh:QD1-999osteoprotegerinOPG/RANKL/RANKCancer researchbiology.proteinBlood VesselsBiomarkers
researchProduct

No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.

2013

OBJECTIVES: The widespread use of tumour necrosis factor (TNF)-targeted therapies in patients with rheumatic, digestive and dermatologic diseases has been associated with reports of reactivation of HBV replication and ensuing hepatitis flares both in asymptomatic HBsAg carriers and in subjects with occult HBV infection. The aim of our work was to investigate in a two-year prospective study the potential for HBV reactivation in patients with inflammatory joint diseases undergoing anti-TNF treatment from a southern Mediterranean area. METHODS: Fifty-seven consecutive outpatients attending the Academic Unit of Rheumatology at the University of Palermo (12 with rheumatoid arthritis, 17 with pso…

AdultMaleHepatitis B virusTime Factorsoccult HBV-DNAAntiviral AgentsPolymerase Chain ReactionRisk AssessmentRisk FactorsRheumatic Diseasesoccult HBV-DNA rheumatic diseases anti-TNFHumansProspective Studiesrheumatic diseaseAcademic Medical CentersHepatitis B Surface AntigensTumor Necrosis Factor-alphavirus diseasesanti-TNFMiddle AgedHepatitis Bdigestive system diseasesTreatment OutcomeItalyLamivudineAntirheumatic AgentsDNA ViralFemaleVirus ActivationBiomarkers
researchProduct

Medikamentöse Schädigung der Leber mit autoimmunem Phänotyp durch TNF-Blockade – Fallvorstellung und Review der Literatur

2014

Die Zulassung von Medikamenten, die die biologische Wirkung von Tumor-Nekrose-Faktor alpha (TNF-α) blockieren, hat die Behandlungsmoglichkeiten von Patienten mit einer Reihe von autoimmun-vermittelten Erkrankungen stark verbessert. Als haufige Nebenwirkung kommt es zu einer gesteigerten Anfalligkeit gegenuber Infekten. Selten treten auch hepatische Nebenwirkungen unter TNF-Blockade auf. Diese reichen von einer moderaten Leberwert- und Bilirubinerhohung uber die Reaktivierung von chronischen Viruserkrankungen, konnen aber auch zum akuten Leberversagen fuhren. In einem Teil der Falle wurde ein autoimmunes Schadigungsmuster mit dem Auftreten von Autoantikorpern und entsprechenden typischen his…

Gynecologymedicine.medical_specialtybusiness.industryGastroenterologymedicineAnti-TNF therapybusinessZeitschrift für Gastroenterologie
researchProduct

Evaluation of Changes in Gut Microbiota in Patients with Crohn’s Disease after Anti-Tnfα Treatment: Prospective Multicenter Observational Study

2020

Background: Crohn’s disease is believed to result from the interaction between genetic susceptibility, environmental factors and gut microbiota, leading to an aberrant immune response. The objectives of this study are to evaluate the qualitative and quantitative changes in the microbiota of patients with Crohn’s disease after six months of anti-tumor-necrosis factor (anti-TNFα) (infliximab or adalimumab) treatment and to determine whether these changes lead to the recovery of normal microbiota when compared to a control group of healthy subjects. In addition, we will evaluate the potential role of the Faecalibacterium prausnitzii/Escherichia coli and Faecalibacterium prausnitzii/Clostridium…

Project ReportCrohn’s diseasemedicine.medical_specialtyanti-TNFαHealth Toxicology and MutagenesisFaecalibacterium prausnitziilcsh:MedicineDiseaseGut flora03 medical and health sciences0302 clinical medicineCrohn DiseaseInternal medicinemedicineAdalimumabEscherichia coli and Clostridium coccoides groupHumansProspective Studies030304 developmental biology0303 health sciencesCrohn's diseasebiologygut microbiotabusiness.industryFaecalibacterium prausnitziiTumor Necrosis Factor-alphalcsh:RPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationInfliximabGastrointestinal MicrobiomeDysbiosis030211 gastroenterology & hepatologyCalprotectinbusinessDysbiosismedicine.drugInternational Journal of Environmental Research and Public Health
researchProduct

Hematopoietic stem cell quiescence and function are controlled by the CYLD–TRAF2–p38MAPK pathway

2015

Tesio at al. identify a novel pathway controlled by the tumor suppressor and deubiquitinase cylindromatosis (CYLD), which is involved in the regulation of hematopoietic stem cell quiescence and repopulation potential.

TRAF2Tumor suppressor geneMAP Kinase Signaling SystemImmunologyRegulatorBiologyp38 Mitogen-Activated Protein KinasesArticleMicemedicineAnimalsImmunology and AllergyMice KnockoutRegulation of gene expressionNF-kappa BHematopoietic stem cellCell BiologyHematopoietic Stem CellsTNF Receptor-Associated Factor 2PhenotypeDeubiquitinating Enzyme CYLDCell biologyCysteine EndopeptidasesHaematopoiesismedicine.anatomical_structureGene Expression RegulationMutationStem cellJournal of Experimental Medicine
researchProduct

Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriati…

2022

Abstract Background Biologics have demonstrated efficacy in PsA in randomized clinical trials. More evidence is needed on their effectiveness under real clinical practice conditions. The aim of the present work is to provide real-world evidence of the effectiveness of biologics for PsA in the daily clinical practice. Methods CHRONOS was a multicenter, non-interventional, cohort study conducted in 20 Italian hospital rheumatology clinics. Results 399 patients were eligible (56.9% females, mean (SD) age: 52.4 (11.6) years). The mean (SD) duration of PsA and psoriasis was 7.2 (6.9) and 15.3 (12.2) years, respectively. The mean (SD) duration of the biologic treatment under analysis was 18.6 (6.…

TNF-inhibitors.ACRBiologicRheumatologyPsoriatic arthritiDAS28Real world evidenceSecukinumabBMC Rheumatology
researchProduct

Acute Myocardial Infarction and Proinflammatory Gene Variants

2007

We identified four genetic risk sets for acute myocardial infarction (AMI) from information on functional gene variants that favor inflammation or modulate cholesterol metabolism: IL6 -174 G/C, TNF -308 G/A, IL10 -1082 G/A, SERPINA3 -51 G/T, IFNG +874 T/A, HMGCR -911 C/A, and APOE ε2/3/4; 316 patients and 461 healthy subjects, all Italian. Putative risk alleles are shown underlined. The sets were identified using grade-of-membership analysis. Membership scores in the sets are automatically generated for individuals. The ''low intrinsic risk'' set had alleles that downregulate inflammation and cholesterol synthesis (IL6, TNF, ILl0, HMGCR). ''AMI across a broad age range'' carried multiple pr…

AdultMaleApolipoprotein EAdolescentMyocardial InfarctionGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokinePathogenesischemistry.chemical_compoundApolipoproteins EHistory and Philosophy of SciencemedicineHumansGenetic Predisposition to DiseaseMyocardial infarctionAge of OnsetAlleleAllelesSerpinsAgedAged 80 and overbusiness.industryCholesterolGeneral NeuroscienceMiddle Agedmedicine.diseaseMiddle ageInterleukin 10CholesterolchemistryAMI Grade of Membership Genetic profile IL6 -174 G/C TNF -308 G/A IL10 -1082 G/A SERPINA3 -51 G/T IFNG +874 T/A HMGCR -911 C/A APOE ε2/3/4Acute DiseaseImmunologyCytokinesFemaleHydroxymethylglutaryl CoA Reductaseslipids (amino acids peptides and proteins)businessAnnals of the New York Academy of Sciences
researchProduct

Interleukin 10 restores lipopolysaccharide-induced alterations in synaptic plasticity probed by repetitive magnetic stimulation

2020

Systemic inflammation is associated with alterations in complex brain functions such as learning and memory. However, diagnostic approaches to functionally assess and quantify inflammation-associated alterations in synaptic plasticity are not well-established. In previous work, we demonstrated that bacterial lipopolysaccharide (LPS)-induced systemic inflammation alters the ability of hippocampal neurons to express synaptic plasticity, i.e., the long-term potentiation (LTP) of excitatory neurotransmission. Here, we tested whether synaptic plasticity induced by repetitive magnetic stimulation (rMS), a non-invasive brain stimulation technique used in clinical practice, is affected by LPS-induc…

lcsh:Immunologic diseases. AllergyLipopolysaccharides0301 basic medicinenon-invasive brain stimulationInterleukin-1betaImmunologyTNFα-reporter mouseMice TransgenicStimulationNeurotransmissionHippocampusSynaptic TransmissionneuroinflammationInterferon-gammaMice03 medical and health sciences0302 clinical medicineGenes Reportertranscranial magnetic stimulationAnimalsImmunology and Allergyddc:610NeuroinflammationOriginal ResearchInflammationNeuronsNeuronal Plasticitysynaptic plasticityInterleukin-6Tumor Necrosis Factor-alphaChemistryLong-term potentiationInterleukin-10Mice Inbred C57BLOrganoids030104 developmental biologyBrain stimulationSynaptic plasticityExcitatory postsynaptic potentialTumor necrosis factor alphaMicrogliainterleukin 10lcsh:RC581-607Neuroscience030217 neurology & neurosurgery
researchProduct